Retrieve available abstracts of 29 articles: HTML format
Single Articles
June 2025
IBRAHIM M, Illa-Bochaca I, Jour G, Vega-Saenz de Miera E, et al NF1 Loss Promotes EGFR Activation and Confers Sensitivity to EGFR Inhibition in
NF1 Mutant Melanoma.
Cancer Res. 2025 Jun 10. doi: 10.1158/0008-5472.CAN-24-3904. PubMedAbstract available
May 2025
GADAL S, Boyer JA, Roy SF, Outmezguine NA, et al Tumorigenesis Driven by BRAFV600E Requires Secondary Mutations That Overcome Its
Feedback Inhibition of RAC1 and Migration.
Cancer Res. 2025;85:1611-1627. PubMedAbstract available
April 2025
SRIVASTAVA J, Yadav VK, Jimenez RV, Phadatare PR, et al Blocking Nitrosylation Induces Immunogenic Cell Death by Sensitizing NRAS-Mutant
Melanoma to MEK Inhibitors.
Cancer Res. 2025 Apr 27. doi: 10.1158/0008-5472.CAN-24-0693. PubMedAbstract available
March 2025
SCORTEGAGNA M, Murad R, Bina P, Feng Y, et al Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma
Progression and Metastasis.
Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-4317. PubMedAbstract available
MAHURON KM, Shahid O, Sao P, Wu C, et al Single Cell Analyses Reveal a Functionally Heterogeneous Exhausted CD8+ T Cell
Subpopulation that is Correlated with Response to Checkpoint Therapy in Melanoma.
Cancer Res. 2025 Mar 5. doi: 10.1158/0008-5472.CAN-23-3918. PubMedAbstract available
OSPINA OE, Manjarres-Betancur R, Gonzalez-Calderon G, Soupir AC, et al spatialGE Is a User-Friendly Web Application That Facilitates Spatial
Transcriptomics Data Analysis.
Cancer Res. 2025;85:848-858. PubMedAbstract available
February 2025
ALLARD D, Cormery J, Bricha S, Fuselier C, et al Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor
Immunity and T-cell Pyrimidine Synthesis.
Cancer Res. 2025;85:692-703. PubMedAbstract available
December 2024
RUBINSTEIN JC, Domanskyi S, Sheridan TB, Sanderson B, et al Spatiotemporal Profiling Defines Persistence and Resistance Dynamics During
Targeted Treatment of Melanoma.
Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-24-0690. PubMedAbstract available
NASCENTES MELO LM, Sabatier M, Ramesh V, Szylo KJ, et al Selenoprotein O Promotes Melanoma Metastasis and Regulates Mitochondrial Complex
II Activity.
Cancer Res. 2024 Dec 19. doi: 10.1158/0008-5472.CAN-23-2194. PubMedAbstract available
FORD CA, Koludrovic D, Centeno PP, Foth M, et al Targeting the PREX2/RAC1/PI3Kbeta Signaling Axis Confers Sensitivity to Clinically
Relevant Therapeutic Approaches in Melanoma.
Cancer Res. 2024 Dec 5. doi: 10.1158/0008-5472.CAN-23-2814. PubMedAbstract available
November 2024
ZHOU Y, Pang L, Ding T, Chen K, et al Precise In Situ Delivery of a Photo-Enhanceable Inflammasome-Activating
Nanovaccine Activates Anticancer Immunity.
Cancer Res. 2024;84:3834-3847. PubMedAbstract available
IZAR B, Kim M Peritumoral Venous Vessels: Autobahn and Portal for T cells to Melanoma Brain
Metastasis.
Cancer Res. 2024 Nov 8. doi: 10.1158/0008-5472.CAN-24-4054. PubMedAbstract available
JASANI N, Xu X, Posorske B, Kim Y, et al PHGDH Induction by MAPK is Essential for Melanoma Formation and Creates an
Actionable Metabolic Vulnerability.
Cancer Res. 2024 Nov 4. doi: 10.1158/0008-5472.CAN-24-2471. PubMedAbstract available
October 2024
BOUKERCHE H, Su ZZ, Emdad L, Sarkar D, et al Retraction: mda-9/Syntenin Regulates the Metastatic Phenotype in Human Melanoma
Cells by Activating Nuclear Factor-kappaB.
Cancer Res. 2024;84:3312. PubMed
September 2024
LI Y, Ming R, Zhang T, Gao Z, et al TCTN1 Induces Fatty Acid Oxidation to Promote Melanoma Metastasis.
Cancer Res. 2024 Sep 26. doi: 10.1158/0008-5472.CAN-24-0158. PubMedAbstract available
OKADA M, Yamasaki S, Nakazato H, Hirahara Y, et al ARID1A-Deficient Tumors Acquire Immunogenic Neoantigens during the Development of
Resistance to Targeted Therapy.
Cancer Res. 2024;84:2792-2805. PubMedAbstract available
July 2024
ENRIQUEZ JA, Mittelbrunn M Warburg Effect Reshapes Tumor Immunogenicity.
Cancer Res. 2024;84:2043-2045. PubMedAbstract available
June 2024
OATMAN N, Gawali MV, Congrove S, Caceres R, et al A multimodal drug-diet-immunotherapy combination restrains melanoma progression
and metastasis.
Cancer Res. 2024 Jun 17. doi: 10.1158/0008-5472.CAN-23-1635. PubMedAbstract available
May 2024
LIU D, Wei B, Liang L, Sheng Y, et al The Circadian Clock Component RORA Increases Immunosurveillance in Melanoma by
Inhibiting PD-L1 Expression.
Cancer Res. 2024 May 8. doi: 10.1158/0008-5472.CAN-23-3942. PubMedAbstract available
April 2024
FRITSCH EF, Ott PA Personalized Cancer Vaccines Directed against Tumor Mutations: Building Evidence
from Mice to Humans.
Cancer Res. 2024;84:953-955. PubMedAbstract available
January 2024
XU X, Bok I, Jasani N, Wang K, et al PTEN Lipid Phosphatase Activity Suppresses Melanoma Formation by Opposing an
AKT/mTOR/FRA1 Signaling Axis.
Cancer Res. 2024 Jan 9:OF1-OF17. doi: 10.1158/0008-5472.CAN-23-1730. PubMedAbstract available
November 2023
TAO H, Jin C, Zhou L, Deng Z, et al PRMT1 inhibition activates the interferon pathway to potentiate antitumor
immunity and enhance checkpoint blockade efficacy in melanoma.
Cancer Res. 2023 Nov 22. doi: 10.1158/0008-5472.CAN-23-1082. PubMedAbstract available
October 2023
BIEBERICH F, Reddy ST The Unexpected Benefit of TCR Cross-Reactivity in Cancer Immunotherapy.
Cancer Res. 2023;83:3168-3169. PubMedAbstract available
September 2023
FERRETTI LP, Bohi F, Leslie Pedrioli DM, Cheng PF, et al Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype
switch-driven drug resistance in advanced melanoma.
Cancer Res. 2023 Sep 20. doi: 10.1158/0008-5472.CAN-23-0485. PubMedAbstract available
SHI J, Jiao T, Guo Q, Weng W, et al A cell surface-binding antibody atlas nominates a MUC18-directed antibody-drug
conjugate for targeting melanoma.
Cancer Res. 2023 Sep 5. doi: 10.1158/0008-5472.CAN-23-1356. PubMedAbstract available
June 2023
ADAKU N, Ostendorf BN, Mei W, Tavazoie SF, et al Apolipoprotein E2 Stimulates Protein Synthesis and Promotes Melanoma Progression.
Cancer Res. 2023 Jun 19:CAN-23-1252. doi: 10.1158/0008-5472.CAN-23-1252. PubMedAbstract available
May 2023
KIM D, An L, Moon J, Maymi VI, et al Ccr2+ monocyte-derived macrophages influence trajectories of acquired therapy
resistance in Braf-mutant melanoma.
Cancer Res. 2023 May 17:CAN-22-2841. doi: 10.1158/0008-5472.CAN-22-2841. PubMedAbstract available
April 2023
PARK HR, Shiva A, Cummings P, Kim S, et al Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell
exclusion and limits immunotherapy in melanoma.
Cancer Res. 2023 Apr 24:CAN-22-2838. doi: 10.1158/0008-5472.CAN-22-2838. PubMedAbstract available
March 2023
EICHHOFF OM, Stoffel CI, Kasler J, Briker L, et al ROS Induction Targets Persister Cancer Cells with Low Metabolic Activity in
NRAS-Mutated Melanoma.
Cancer Res. 2023 Mar 22:OF1-OF19. doi: 10.1158/0008-5472.CAN-22-1826. PubMedAbstract available